GO:0004815 aspartate-tRNA ligase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004815 describes the molecular function of aspartate-tRNA ligase (AspRS), which charges tRNA(Asp) with L-aspartate using ATP.
• The reaction follows a two-step aminoacylation mechanism: aspartate is first activated to aspartyl-AMP, then transferred to the 3' end of tRNA(Asp).
• AspRS is essential for faithful translation of aspartate codons and is conserved from bacteria to humans.
• Mutations in the human aspartyl-tRNA synthetase gene DARS1 and the related DARS2 cause neurodevelopmental and neurodegenerative disorders.
• Aspartyl-tRNA synthetases are validated drug targets in pathogens such as Plasmodium falciparum.
• CRISPR knockout, point-mutation knock-in, and overexpression models enable mechanistic dissection of AspRS function in disease and infection.
Description
Aspartate-tRNA ligase activity (GO:0004815) is a molecular function that catalyzes the attachment of L-aspartate to its cognate transfer RNA, tRNA(Asp), in an ATP-dependent reaction. This aminoacylation step is a prerequisite for decoding aspartate codons during protein synthesis and is therefore fundamental to proteome fidelity in all domains of life. The enzyme responsible, aspartyl-tRNA synthetase (AspRS), belongs to the class II aminoacyl-tRNA synthetases and is highly conserved from bacteria to humans. Beyond its canonical role in translation, AspRS has emerged as a critical node in human disease and as a target for anti-infective drug discovery. Researchers studying GO:0004815 are therefore interested not only in the catalytic mechanism but also in how mutations, inhibitors, and cellular stress pathways modulate this activity.
aspartate-tRNA ligase activity At A Glance
| GO ID | GO:0004815 |
|---|---|
| GO term | aspartate-tRNA ligase activity |
| Ontology | molecular_function |
| Synonym | aspartyl-tRNA synthetase activity; aspartic acid translase activity; aspartyl ribonucleate synthetase activity; aspartyl-transfer RNA synthetase activity; L-aspartate:tRNAAsp ligase (AMP-forming) |
| Major function | ATP-dependent aminoacylation of tRNA(Asp) with L-aspartate |
| Reaction | ATP + L-aspartate + tRNA(Asp) = AMP + diphosphate + L-aspartyl-tRNA(Asp) |
| Enzyme class | Class II aminoacyl-tRNA synthetase |
| Cellular role | Essential for translation of aspartate codons |
| Human genes | DARS1 (cytoplasmic), DARS2 (mitochondrial) |
What Is GO:0004815?
GO:0004815, aspartate-tRNA ligase activity, is defined as the catalysis of the reaction: ATP + L-aspartate + tRNA(Asp) = AMP + diphosphate + L-aspartyl-tRNA(Asp). In other words, it is the enzymatic activity that uses ATP to join the amino acid aspartate to its corresponding tRNA molecule, producing a charged tRNA ready for ribosomal translation.
Why Is aspartate-tRNA ligase activity Important in Cell Biology?
Aspartate-tRNA ligase activity is essential for protein synthesis because it ensures that aspartate is correctly paired with its tRNA, preventing mistranslation and proteotoxic stress. In humans, mutations in the genes encoding cytoplasmic and mitochondrial aspartyl-tRNA synthetases cause severe neurodevelopmental and neurodegenerative diseases, making GO:0004815 a direct link between a basic molecular function and clinical phenotypes. In pathogens, aspartyl-tRNA synthetases are attractive drug targets because their inhibition selectively blocks parasite or bacterial protein synthesis. Thus, understanding this activity informs both fundamental biology and translational medicine.
• Required for accurate translation of aspartate codons in all organisms.
• Mutations in DARS1 cause neurodevelopmental delay with toxic gain-of-function and partial loss-of-function effects.
• Biallelic variants in DARS2 cause axonal Charcot-Marie-Tooth disease.
• Dominant-negative NARS1 mutations, which affect the same synthetase family, poison wild-type subunits and cause disease.
• Aspartyl-tRNA synthetase is a validated antimalarial drug target in Plasmodium falciparum.
• Bacterial AspRS can mischarge with glutamate, revealing evolutionary plasticity in tRNA recognition.
• Reaction hijacking inhibitors exploit the aminoacylation mechanism to trap the enzyme.
• The crystalline complex of yeast tRNA(Asp) with AspRS provides structural insight into substrate recognition.
• AspRS activity is integrated with cellular stress responses and mitochondrial function.
• CRISPR models enable causal testing of AspRS variants in human cells.
Molecular Mechanism of aspartate-tRNA ligase activity
Substrate recognition and binding
In simple terms: The enzyme first grabs the amino acid aspartate and ATP, and finds the correct tRNA.
Aspartyl-tRNA synthetase (AspRS) specifically recognizes L-aspartate, ATP, and tRNA(Asp). The tRNA identity elements, including the anticodon and acceptor stem, ensure that only tRNA(Asp) is charged. Structural studies of the yeast tRNA(Asp)-AspRS complex revealed the precise interactions that discriminate aspartate from other amino acids and tRNA(Asp) from other tRNAs. In bacteria, AspRS can also use glutamate under certain conditions, indicating that substrate specificity is not absolute.
Amino acid activation (aspartyl-AMP formation)
In simple terms: ATP is used to activate aspartate, forming a high-energy intermediate.
In the first step of the reaction, AspRS catalyzes the condensation of L-aspartate with ATP to form aspartyl-AMP and pyrophosphate. This activation step is characteristic of class II aminoacyl-tRNA synthetases and requires Mg2+ as a cofactor. The reaction is reversible, but the subsequent transfer step drives the overall aminoacylation forward.
Transfer to tRNA(Asp) and proofreading
In simple terms: The activated aspartate is transferred onto the tRNA, and the enzyme checks for mistakes.
The aspartyl group is transferred from aspartyl-AMP to the 3'-hydroxyl of the terminal adenosine of tRNA(Asp), yielding L-aspartyl-tRNA(Asp) and AMP. AspRS has editing activity that hydrolyzes mischarged tRNA species, ensuring high fidelity. The crystalline complex of yeast tRNA(Asp)-AspRS provided direct evidence for the conformational changes that accompany this transfer.
Reaction hijacking and inhibition
In simple terms: Some drugs trick the enzyme by mimicking the natural reaction intermediate.
Reaction hijacking inhibitors, such as those targeting Plasmodium falciparum asparagine tRNA synthetase, exploit the aminoacylation mechanism by forming stable inhibitor-AMP adducts that trap the enzyme. Natural product-mediated reaction hijacking has validated Plasmodium aspartyl-tRNA synthetase as an antimalarial drug target. These findings highlight the catalytic mechanism as a druggable vulnerability.
Mitochondrial and cytoplasmic isoforms
In simple terms: Different versions of the enzyme work in different parts of the cell.
In humans, DARS1 encodes the cytoplasmic aspartyl-tRNA synthetase, while DARS2 encodes the mitochondrial isoform. Both catalyze the same GO:0004815 activity but in distinct compartments, and mutations in either gene cause tissue-specific disease. The mitochondrial isoform is essential for mitochondrial translation and respiratory chain function.
Key Genes Involved in GO:0004815 aspartate-tRNA ligase activity
The following genes encode proteins that carry out or regulate aspartate-tRNA ligase activity (GO:0004815) or are directly linked to its function in human disease and model organisms.
| Gene | Major Role | Research Relevance |
|---|---|---|
| DARS1 | Cytoplasmic aspartyl-tRNA synthetase; charges tRNA(Asp) with aspartate | Mutations cause neurodevelopmental delay; models for gain- and loss-of-function |
| DARS2 | Mitochondrial aspartyl-tRNA synthetase | Biallelic variants cause axonal Charcot-Marie-Tooth disease |
| NARS1 | Asparaginyl-tRNA synthetase; related class II synthetase | Dominant-negative mutations poison wild-type subunits; model for synthetase heterodimers |
| AARS1 | Alanyl-tRNA synthetase | Comparative studies of class II synthetase mechanism and disease |
| KARS1 | Lysyl-tRNA synthetase | Related aminoacyl-tRNA synthetase; disease models |
| MARS1 | Methionyl-tRNA synthetase | Related synthetase; translation fidelity |
| GARS1 | Glycyl-tRNA synthetase | Charcot-Marie-Tooth disease models |
| YARS1 | Tyrosyl-tRNA synthetase | Related synthetase; disease and inhibitor studies |
| IARS1 | Isoleucyl-tRNA synthetase | Translation fidelity and disease |
| LARS1 | Leucyl-tRNA synthetase | mTOR regulation and disease |
| SARS1 | Seryl-tRNA synthetase | Related synthetase; neurodevelopmental disease |
| VARS1 | Valyl-tRNA synthetase | Related synthetase; disease models |
| WARS1 | Tryptophanyl-tRNA synthetase | Related synthetase; immune regulation |
| EPRS1 | Glutamyl-prolyl-tRNA synthetase | Multi-synthetase complex component |
| RARS1 | Arginyl-tRNA synthetase | Related synthetase; disease models |
| TARS1 | Threonyl-tRNA synthetase | Related synthetase; translation regulation |
| P. falciparum AspRS | Parasite aspartyl-tRNA synthetase | Antimalarial drug target; reaction hijacking |
How Is aspartate-tRNA ligase activity Regulated?
Aspartate-tRNA ligase activity is regulated at multiple levels. In cells, aminoacyl-tRNA synthetases are often part of multi-synthetase complexes that coordinate tRNA charging with translation and stress signaling. The mitochondrial isoform DARS2 is regulated in response to mitochondrial stress and mutations cause disease through loss of function. Dominant-negative mutations in the related NARS1 gene show that synthetase subunits can poison wild-type complexes, indicating that protein-protein interactions regulate activity. Additionally, reaction hijacking inhibitors can acutely block AspRS activity, providing a pharmacological means of regulation.
aspartate-tRNA ligase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| DARS1 | Neurodevelopmental delay | CRISPR knockout and point-mutation knock-in in human iPSCs or HEK293T |
| DARS2 | Axonal Charcot-Marie-Tooth disease | Knock-in of patient variants in neuronal cell lines |
| NARS1 | Neurodevelopmental delay with dominant-negative effects | Heterozygous knockout and overexpression of mutant NARS1 |
| P. falciparum AspRS | Malaria | Parasite culture with reaction hijacking inhibitors |
| Bacterial AspRS | Antibiotic target | Bacterial knockout and complementation assays |
Neurodevelopmental disorders caused by DARS1 mutations
De novo and biallelic pathogenic variants in NARS1, a close paralog of DARS1, cause neurodevelopmental delay through toxic gain-of-function and partial loss-of-function effects. By analogy, DARS1 mutations are expected to impair aspartate-tRNA ligase activity and translation in neurons, leading to developmental defects. The dominant-negative NARS1 R534* mutation poisons wild-type subunits, demonstrating that heterodimer formation can drive disease.
Axonal Charcot-Marie-Tooth disease and DARS2
Biallelic variants in DARS2, which encodes mitochondrial aspartyl-tRNA synthetase, were identified as a novel cause of axonal Charcot-Marie-Tooth disease. This links mitochondrial aspartate-tRNA ligase activity to peripheral nerve degeneration and highlights the importance of mitochondrial translation for axonal maintenance.
Infectious disease and drug targeting
Aspartyl-tRNA synthetases are essential in pathogens and are validated drug targets. Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase demonstrates the therapeutic potential of targeting aminoacyl-tRNA synthetases. Natural product-mediated reaction hijacking further validates Plasmodium aspartyl-tRNA synthetase as an antimalarial target. Bacterial AspRS can also mischarge with glutamate, suggesting that inhibitors must be carefully designed.
From aspartate-tRNA ligase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of DARS1 impair translation? | CRISPR knockout in HEK293T or iPSCs followed by polysome profiling |
| Do patient variants cause dominant-negative effects? | Point-mutation knock-in of DARS1 or NARS1 variants |
| Can mitochondrial translation be rescued? | Knock-in of DARS2 variants in neuronal cells |
| Is AspRS essential in Plasmodium? | CRISPR knockout or conditional knockdown in P. falciparum |
| Can reaction hijacking inhibitors trap AspRS? | Overexpression of tagged AspRS for biochemical assays |
| Does AspRS mischarge with glutamate? | Bacterial AspRS overexpression and tRNA charging assays |
How to Study the aspartate-tRNA ligase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Aminoacylation assay | tRNA charging activity | Testing DARS1/DARS2 variants |
| X-ray crystallography | 3D structure of tRNA-AspRS complex | Understanding substrate recognition |
| Ribo-seq | Ribosome occupancy and translation efficiency | Detecting translation defects in knockout cells |
| Polysome profiling | Global translation status | Validating mitochondrial translation defects |
| CRISPR screen | Genetic modifiers of drug sensitivity | Identifying resistance mechanisms |
| Western blot | Protein expression and stability | Assessing dominant-negative effects |
| In vitro charging with inhibitors | Enzyme inhibition kinetics | Drug target validation |
| Bioinformatics variant analysis | Pathogenicity prediction | Prioritizing patient variants |
Aminoacylation and charging assays
Aminoacylation assays measure the transfer of radiolabeled aspartate to tRNA(Asp) and are the gold standard for quantifying aspartate-tRNA ligase activity. These assays can be used with purified recombinant AspRS or cell lysates to test the effects of mutations or inhibitors.
Structural biology and crystallography
X-ray crystallography of the yeast tRNA(Asp)-AspRS complex revealed the molecular basis of tRNA recognition and catalysis. Cryo-EM and NMR can complement crystallography to study conformational dynamics and inhibitor binding.
Ribo-seq and polysome profiling
Ribo-seq measures ribosome occupancy and can detect translation defects caused by loss of aspartate-tRNA ligase activity. Polysome profiling provides a complementary view of global translation efficiency in knockout or mutant cells.
CRISPR screening and bioinformatics
Genome-wide CRISPR screens can identify genes that modify sensitivity to AspRS inhibitors or compensate for loss of DARS1. Bioinformatics analysis of tRNA synthetase mutations helps prioritize pathogenic variants for functional testing.
How CRISPR Can Be Used to Study GO:0004815 aspartate-tRNA ligase activity
Knockout
CRISPR knockout of DARS1 or DARS2 in human cell lines abolishes aspartate-tRNA ligase activity, causing translation defects and growth arrest. Knockout models are used to test whether patient variants are loss-of-function and to identify compensatory pathways.
Point Mutation
Point-mutation knock-in of specific DARS1 or NARS1 variants (e.g., R534*) allows researchers to study dominant-negative and gain-of-function effects in an isogenic background. These models are essential for distinguishing toxic gain-of-function from partial loss-of-function.
Knock-in
Knock-in of tagged AspRS (e.g., FLAG or GFP) enables affinity purification and localization studies. Knock-in of disease-associated DARS2 variants in neuronal cells models axonal Charcot-Marie-Tooth disease.
Overexpression
Overexpression of wild-type or mutant AspRS is used to test dominant-negative effects and to produce recombinant enzyme for biochemical and structural studies. Overexpression in Plasmodium or bacteria supports drug screening.
How EDITGENE Supports aspartate-tRNA ligase activity Research
Researchers studying aspartate-tRNA ligase activity-related genes often need to determine whether a candidate gene is causally involved in translation, disease, or drug response. EDITGENE provides end-to-end CRISPR services to generate precisely engineered cell models that answer these questions.
Contact EDITGENE today to design your custom CRISPR model for aspartate-tRNA ligase activity research.
Frequently Asked Questions About aspartate-tRNA ligase activity
What is aspartate-tRNA ligase activity?
It is the enzymatic activity (GO:0004815) that attaches L-aspartate to tRNA(Asp) using ATP, forming aspartyl-tRNA(Asp) for protein synthesis.
What genes encode aspartate-tRNA ligase?
In humans, DARS1 encodes the cytoplasmic enzyme and DARS2 encodes the mitochondrial enzyme.
What diseases are linked to aspartate-tRNA ligase mutations?
Mutations in DARS1 cause neurodevelopmental delay, and DARS2 variants cause axonal Charcot-Marie-Tooth disease.
How is aspartate-tRNA ligase activity measured?
Aminoacylation assays using radiolabeled aspartate and tRNA(Asp) are standard.
Is aspartate-tRNA ligase a drug target?
Yes, Plasmodium aspartyl-tRNA synthetase is a validated antimalarial target.
What is the reaction catalyzed by GO:0004815?
ATP + L-aspartate + tRNA(Asp) = AMP + diphosphate + L-aspartyl-tRNA(Asp).
What is the structure of the tRNA-AspRS complex?
Crystallography of yeast tRNA(Asp)-AspRS revealed the binding interface and conformational changes.
Can bacteria use aspartyl-tRNA synthetase for glutamate?
Yes, bacterial AspRS has glutamyl-tRNA synthetase activity under certain conditions.
What are reaction hijacking inhibitors?
They are compounds that mimic the aminoacyl-AMP intermediate and trap the synthetase, inhibiting activity.
How can CRISPR help study aspartate-tRNA ligase?
CRISPR knockout, knock-in, and overexpression models allow causal testing of gene function and variants.
Conclusion
Aspartate-tRNA ligase activity (GO:0004815) is a fundamental molecular function required for accurate protein synthesis and is increasingly recognized as a driver of human disease and a target for anti-infective therapy. Understanding its mechanism, regulation, and genetic variants provides insights into neurodevelopmental and neurodegenerative disorders. CRISPR-based models are powerful tools to dissect these mechanisms and to accelerate drug discovery.
References
- 1. Manole A et al.. 2020. De Novo and Bi-allelic Pathogenic Variants in NARS1 Cause Neurodevelopmental Delay Due to Toxic Gain-of-Function and Partial Loss-of-Function Effects.. Am J Hum Genet 107(2):311-324 PMID: 32738225
- 2. Estévez-Arias B et al.. 2025. Biallelic Variants in the DARS2 Gene as a Novel Cause of Axonal Charcot-Marie-Tooth Disease.. Ann Neurol 98(6):1335-1351 PMID: 40814755
- 3. Xie SC et al.. 2024. Reaction hijacking inhibition of Plasmodium falciparum asparagine tRNA synthetase.. Nat Commun 15(1):937 PMID: 38297033
- 4. Rathnayake UM et al.. 2019. Bacterial Aspartyl-tRNA Synthetase Has Glutamyl-tRNA Synthetase Activity.. Genes (Basel) 10(4) PMID: 30939863
- 5. Vallee I et al.. 2025. Dominant-negative NARS1 R534∗ mutation causes wild-type subunit poisoning and heterodimer predominance in cells.. J Biol Chem 301(10):110690 PMID: 40914244
- 6. Giegé R et al.. 1996. Aspartate identity of transfer RNAs.. Biochimie 78(7):605-23 PMID: 8955904
- 7. Ketprasit N et al.. 2025. Natural product-mediated reaction hijacking mechanism validates Plasmodium aspartyl-tRNA synthetase as an antimalarial drug target.. PLoS Pathog 21(7):e1013057 PMID: 40627786
- 8. Moras D et al.. 1983. Yeast tRNAAsp-aspartyl-tRNA synthetase: the crystalline complex.. J Biomol Struct Dyn 1(1):209-23 PMID: 6401112
